Cardiovascular Diseases

Research Line


The cardiovascular health activities are in response to the growing burden of these diseases due to the social, demographic, epidemiologic and health care transitions that have led to cardiovascular diseases being the number one cause of death in the country.

The activities are dedicated to:

  • Providing a platform for cardiovascular health research that is relevant to resource-limited settings
  • Focusing on key individual determinants (tobacco, diet, physical activity and psychological factors) as well as underlying social determinants (‘causes of causes’)
  • Providing a robust training environment that will foster a new generation of scholars engaged in cardiovascular research
  • Enhancing the translation and dissemination of research findings among vulnerable populations
  • Achieving a reputation for excellence in cardiovascular health research
Sl No. Project Title Project Lead Year
1 Early detection of hypertension during pregnancy using increased frequency of blood pressure monitoring and information technology: A single group, prospective observational pilot study Dr. Abijeet V Waghmare, Dr. Tony D S Raj, Dr. Kedar Radhakrishna 2014
2 Improving mental health through integration with primary care in rural Karnataka, India Dr. Prem K Mony 2014
3 The International Polycap Study 3 Dr. Prem Pais 2012
4 Situational analysis of the PracticE patterns in Cardiovascular disease managemenT in all Regions of India Using Mixed research methods (SPECTRUM) Dr. Denis Xavier 2012
5 Peri-Operative ISchemic Evaluation‐2 Trial (POISE-2) Dr. Denis Xavier 2012
6 A pilot study for the Early Diagnosis & Prevention System (EDPS) Dr. Denis Xavier 2011
7 A Prospective Study of Practice Patterns and Outcomes in Chronic Disease in an Urban Family Practice (FRIENDS) Dr. Denis Xavier 2010
8 An ongoing program (research, patient management strategies) to prevent & manage Cardiovascular diseases in India (AMEND Program). Dr. Denis Xavier 2010
9 Aliskiren Prevention Of Later Life Outcomes (APOLLO) Dr. Prem Pais, Dr. Denis Xavier 2010
10 A comparative study between standard and high dose of clopidogrel in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy (CURRENT / OASIS-7) Dr. Prem Pais, Dr. Denis Xavier 2009
11 A randomized controlled trial of multi-vitamins vs placebo in secondary stroke prevention (VITATOPS) Dr. Prem Pais 2009
12 INdian Stroke ProspectIve REgistry (INSPIRE) Dr. Prem Pais, Dr. Denis Xavier 2009
13 Primary pREvention strategies at the community level to Promote treatment Adherence to pREvent cardiovascular disease (PREPARE) Dr. Prem Pais, Dr. Denis Xavier 2009
14 An observational study to determine predisposing conditions & regional variations in Atrial Fibrillation/flutter (RELY AF Registry) Dr. Prem Pais, Dr. Denis Xavier 2009
15 A randomized controlled trial of timing of Intervention (early versus delayed) in Acute Coronary Syndromes (TIMACS) Dr. Prem Pais, Dr. Denis Xavier 2009


Sl No. Title Authors Journal Name Publication Year
1 Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW BMJ 2016
2 The association of severity of retinal vascular changes and cardiac remodelling in systemic hypertension Varghese M, Adhyapak SM, Thomas T, Sunder M, Varghese K Ther Adv Cardiovasc Dis 2016
3 Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations Gaziano TA, Abrahams-Gessel S, Alam S, Alam D, Ali M, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gutierrez L, Irazola V, Levitt NS, Miranda JJ, Bernabe-Ortiz A, Pandya A, Rubinstein A, Steyn K, Xavier D, Yan LL Glob Heart 2016
4 Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ Lancet 2016
5 Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, et al. N Engl J Med 2016
6 Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America Carrillo-Larco RM, Miranda JJ, Li X, Cui C, Xu X, Ali M, Alam DS, Gaziano TA, Gupta R, Irazola V, Levitt NS, Prabhakaran D, Rubinstein A, Steyn K, Tandon N, Xavier D, Wu Y, Yan LL Glob Heart 2016
7 Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, et al. N Engl J Med 2016
8 Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies Mente A, O'Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, Mony P, Yusuf S, et al, Lancet 2016
9 Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, et al. N Engl J Med 2016
10 A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale Rao MP, Ciobanu AO, Lopes RD, Fox KA, Xian Y, Pokorney SD, Al-Khalidi HR, Jiang J, Kamath DY, Berwanger O, Xavier D, Bahit CM, Tajer C, Vinereanu D, Huo Y, Granger CB Am Heart J 2016
11 Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial Xavier D, Gupta R, Kamath D, Sigamani A, Devereaux PJ, George N, Joshi R, Pogue J, Pais P, Yusuf S Lancet Diabetes Endocrinol 2016
12 Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, Levitt NS, Miranda JJ, Ortiz AB, Steyn K, Wu Y, Xavier D, Yan LL, He J, Rubinstein A Glob Heart 2016
13 High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective Kamath DY, Xavier D, Sigamani A, Pais P Indian J Med Res 2015
14 Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L Am Heart J 2015
15 Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics Lonn E, Bosch J, Pogue J, Pais P, Xavier D, Yusuf S, et al. Can J Cardiol 2015